Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 07/29/26
Ionis reports second quarter 2026 financial results and highlights progress on key programsBusiness Wire • 07/29/26
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSSGlobeNewsWire • 07/28/26
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSSPRNewsWire • 07/23/26
Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to DeclineZacks Investment Research • 07/22/26
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study DataZacks Investment Research • 07/15/26
Levi & Korsinsky Notifies Investors of a Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals (IONS)GlobeNewsWire • 07/14/26
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's DiseaseBusiness Wire • 07/14/26
IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)Business Wire • 07/13/26
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndromeBusiness Wire • 07/13/26
Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)PRNewsWire • 07/10/26
AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't PanicSeeking Alpha • 07/09/26
Levi Strauss, Ionis Pharmaceuticals, Gloo Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga • 07/09/26
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathyBusiness Wire • 07/09/26